Global Gastrointestinal Stromal Tumors Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Therapy;

Targeted Therapy, Chemotherapy, and Radiation Therapy.

By Indication;

Stomach, Small Intestine, Large Intestine (Colon), and Others.

By End User;

Hospitals & Clinics, Ambulatory Surgical Centers, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn127723968 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Gastrointestinal Stromal Tumors Market (USD Million), 2021 - 2031

In the year 2024, the Global Gastrointestinal Stromal Tumors Market was valued at USD 1,452.01 million. The size of this market is expected to increase to USD 2,271.28 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.6%.

The global gastrointestinal stromal tumors (GIST) market is a dynamic and evolving sector within the oncology landscape, characterized by a growing understanding of tumor biology, advancements in diagnostic techniques, and the emergence of targeted therapies. GISTs, a rare type of cancer that originates in the gastrointestinal tract, particularly the stomach and small intestine, have garnered increasing attention in recent years due to their unique molecular characteristics and treatment challenges. This market is witnessing significant growth driven by a combination of factors including rising incidence rates, improved diagnosis, and expanding treatment options, offering renewed hope for patients battling this disease.

One of the key drivers shaping the GIST market is the growing incidence of gastrointestinal stromal tumors worldwide. While GISTs are relatively rare compared to other cancers, their incidence has been steadily increasing over the past few decades. This trend is attributed to improved detection methods such as endoscopic imaging, better awareness among healthcare professionals, and possibly changes in environmental and lifestyle factors. As more cases are diagnosed at an early stage, there is a growing need for effective treatment options to improve patient outcomes and quality of life.

The landscape of GIST treatment has been revolutionized by the advent of targeted therapies, particularly tyrosine kinase inhibitors (TKIs), which have transformed the management of advanced or metastatic GISTs. Drugs such as imatinib, sunitinib, and regorafenib have demonstrated significant efficacy in inhibiting the aberrant signaling pathways implicated in GIST progression, leading to prolonged progression-free survival and improved overall survival rates. Additionally, ongoing research efforts aimed at identifying novel therapeutic targets and developing combination therapies hold promise for further advancing the treatment paradigm in GIST. As the understanding of GIST biology deepens and precision medicine approaches continue to evolve, the global market for gastrointestinal stromal tumors is poised for continued growth and innovation in the coming years.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Therapy
    2. Market Snapshot, By Indication
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Global Gastrointestinal Stromal Tumors Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Incidence of Gastrointestinal Stromal Tumors
        2. Rising Adoption of Minimally Invasive Surgery
        3. Expanding Research on Biomarkers
        4. Growing Focus on Personalized Medicine
      2. Restraints
        1. High Cost of Targeted Therapies
        2. Challenges in Early Diagnosis
        3. Adverse Effects Associated with Treatment
        4. Regulatory Hurdles for Drug Approval
      3. Opportunities
        1. Expansion into Emerging Markets
        2. Integration of Artificial Intelligence in Diagnosis
        3. Collaboration for Clinical Trials
        4. Patient Education and Support Initiatives
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Gastrointestinal Stromal Tumors Market, By Therapy, 2021 - 2031 (USD Million)
      1. Targeted Therapy
      2. Chemotherapy
      3. Radiation Therapy
    2. Global Gastrointestinal Stromal Tumors Market, By Indication, 2021 - 2031 (USD Million)
      1. Stomach
      2. Small Intestine
      3. Large Intestine (Colon)
      4. Others
    3. Global Gastrointestinal Stromal Tumors Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals & Clinics
      2. Ambulatory Surgical Centers
      3. Others
    4. Global Gastrointestinal Stromal Tumors Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Bayer AG
      2. Novartis AG
      3. Immunicum AB
      4. F. Hoffmann-La Roche Ltd
      5. AB SCIENCES
      6. Arog Pharmaceuticals
      7. Boston Biomedical
      8. Sun Pharmaceutical Industries Limited
      9. Pfizer
  7. Analyst Views
  8. Future Outlook of the Market